Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/5/2011

SAN FRANCISCO, Jan. 5, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 29th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tuesday, January 11, 2011 at 8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 12, 2011.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 development program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects. The company has additional pain compounds in preclinical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors. NKTR-181, a novel mu-opioid analgesic molecule, is currently in IND-enabling studies and Nektar plans to begin Phase 1 clinical studies in the first part of 2011.  

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- The Eastern European medical device industry is in ... as new medical-device manufacturers are constantly trying to penetrate ... to reduce the cost incurred for placing their products ... effective means to achieve this target. This research service ... and provides profiles of key distributors in ...
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, ... America , has launched FluFree.com, a website designed ... vaccinations. For 20 years, Passport Health has ... the flu. The launch of FluFree.com is designed to ... and the number of people who actually chose to ...
(Date:9/30/2014)... Ind. , Sept. 30, 2014  The orthopedic specialists ... the nation,s No. 6 orthopedic group by US News ... Active Adults," a series of free, public seminars to ... all over the world come to see the knee ... procedures are now available at Munster Specialty Surgery Center. ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2
... 2011 Actavis, an international generic pharmaceutical company, today ... Extended-Release Tablets, a generic equivalent of Keppra XR®.  Shipping ... US total sales of approximately $161 million for the ... Health.   About Actavis: ...
... iKnowMed Electronic Health Record System (EHR) ... McKesson Specialty Health Solutions for Oncology , ... comprehensive chemotherapy orders workflow management system. Oncologists with both products ... which now automatically communicates with Lynx Mobile. This way, when ...
Cached Medicine Technology:Actavis Launches Generic Keppra XR® Tablets in the U.S. 2iKnowMed™ Integrates with Lynx Mobile® to Advance a Comprehensive Chemotherapy Management System 2iKnowMed™ Integrates with Lynx Mobile® to Advance a Comprehensive Chemotherapy Management System 3
(Date:9/30/2014)... Dennis Thompson HealthDay Reporter ... first confirmed case of Ebola has surfaced in the United ... federal health officials announced late Tuesday. The critically ill ... Dallas, has been diagnosed with the deadly virus, officials ... in a late afternoon news conference. The man is ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... in 2003 to slow the spiraling costs of drugs ... patients has had no meaningful impact on cancer chemotherapy ... Journal of Clinical Oncology published online today. ... treat colorectal and lung cancers, and did not find ... following the implementation of the recent Medicare law in ...
(Date:9/30/2014)... Sept. 30, 2014 Research by UC Irvine immunologists ... shedding light on a vital process that determines how ... the online version of Nature Immunology , neurology ... other Institute for Immunology colleagues describe a critical mechanism ... into the bloodstream. , A T cell is a ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... by certified nutrition specialist and best-selling author Mike Geary that ... and totally transform their body into a fat-burning machine in ... Michaels, prompting an investigative review. , “In our culture ... it can be hard to decipher what is really fact ...
Breaking Medicine News(10 mins):Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3
... risk of developing obesity. In the current issue of ... colleagues from Witten/Herdecke University describe possible ways to prevent ... 268-75). , There are many reasons that a ... the disability itself, for example, if this includes the ...
... ... Your Story” Diamond Contest. Shenoa will give away a 1-carat diamond ... to win the diamond contestants need only write a short story. Consumer ... is a way to show consumers they are appreciated by Shenoa. ...
... new study shows that a family of molecules called ... many important functions in healthy cells, but that in ... , The research, led by scientists at the Ohio ... and Richard J. Solove Research Institute in collaboration with ...
... mysteries of the animal world: why do females change the ... all year round? Researchers at the University of Gothenburg, Sweden, ... found some of the answers. What can millimetre-long water ... south-west Sweden have to say about animals, winter and summer ...
... from seven founding universities of the Global Alliance of ... at Shanghai Jiao Tong University to hold the 2010 ... Sustainable Urban Solutions. The latter coincides with ... Better Life. Senior representatives discussed the role of technological ...
... parents need more help with lifesaving drug regimens, study ... new study suggests that parents often make mistakes when ... , "Giving these medicines in exactly the right way ... conditions," said study lead author Dr. Kathleen E. Walsh, ...
Cached Medicine News:Health News:ShenoaDiamonds.com Holds Contest to Give Away $5,000 Diamond Ring, Spurred by Online Sales Growth 2Health News:Cancer cells show rewired, fragmented microRNA networks 2Health News:Large caps this spring's must-have for water fleas 2Health News:Global Alliance of Technological Universities (GlobalTech) to tackle 'Grand Challenges' 2Health News:Parent Error Common When Medicating Chronically Ill Kids 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: